Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3864 Target Snapshot

Tyrosine-protein phosphatase non-receptor type 11 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,885Compounds
532Assays
2Approved Drugs
4,886.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Tyrosine-protein phosphatase non-receptor type 11 shows clinical signal disease relevance led by neoplasm. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q06124. Start with neoplasm, then reuse UniProt Q06124 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt Q06124 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
neoplasm

Tyrosine-protein phosphatase non-receptor type 11 shows clinical signal disease relevance led by neoplasm. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include BATOPROTAFIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein phosphatase non-receptor type 11 as ChEMBL target CHEMBL3864, mapped to UniProt Q06124. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein phosphatase non-receptor type 11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3864
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q06124
Tyrosine-protein phosphatase non-receptor type 11
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein phosphatase non-receptor type 11 is the right protein anchor across sources, using UniProt Q06124 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTyrosine-protein phosphatase non-receptor type 11
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ06124
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein phosphatase non-receptor type 11
UniProt AccessionQ06124
Component TypeProtein
Sequence Length593 aa

Tyrosine-protein phosphatase non-receptor type 11

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Tyrosine-protein phosphatase non-receptor type 11, mapped to UniProt Q06124. Sequence length is 593 aa.

Mapped IDQ06124
Review nameTyrosine-protein phosphatase non-receptor type 11
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Tyrosine-protein phosphatase non-receptor type 11 shows clinical signal disease relevance led by neoplasm. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugBATOPROTAFIB
Clinical signal Phase I
kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBATOPROTAFIB
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBATOPROTAFIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include BATOPROTAFIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
5
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC504,799.0
KI31.0
EC5016.0
KD40.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4858291 10.77 IC50 0.017 Preclinical
CHEMBL4752026 10.23 IC50 0.0583 Preclinical
CHEMBL5618733 9.89 IC50 0.13 Preclinical
CHEMBL5618343 9.89 IC50 0.13 Preclinical
CHEMBL4060033 9.84 IC50 0.145 Preclinical
CHEMBL5619476 9.77 IC50 0.17 Preclinical
CHEMBL4871539 9.7 IC50 0.202 Preclinical
CHEMBL5784512 9.52 IC50 0.3 Preclinical
CHEMBL5595838 9.43 Kd 0.37 Preclinical
CHEMBL5183738 9.4 IC50 0.4 Preclinical
Distribution

pChEMBL Value Distribution

578
5.0
382
5.5
422
6.0
373
6.5
422
7.0
351
7.5
336
8.0
91
8.5
32
9.0
6
9.5
pChEMBL
Assay Landscape

Assay Landscape

535
Total Assays
2,346
Tested Compounds
3
Assay Types
Binding — 532 assays, 2,346 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 329 1,980 6.5
cell-based format 133 134 6.8
assay format 69 232 6.4
tissue-based format 1 0 —
Functional — 2 assays, 162 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 162 5.5
ADME — 1 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 11 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine